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OBJECTIVES: To explore the effects of serum from patients with ankylosing spondylitis on the canonicalWnt/b-catenin
pathway and to assess whether the serum has an osteogenic effect in MG63 cells.
METHODS:MG63 cells were cultured with serum from 45 ankylosing spondylitis patients, 30 healthy controls, or
45 rheumatoid arthritis patients. The relative PPARD, fra-1, MMP7, OPG and RANKL mRNA levels were measured
using quantitative real-time polymerase chain reaction. Associations between gene expression and patient
demographics and clinical assessments were then analyzed.
RESULTS:MG63 cells treated with serum from ankylosing spondylitis patients had higher PPARD, fra-1, MMP7 and
OPG gene expression than did cells treated with serum from controls or rheumatoid arthritis patients (all po0.05).
RANKL expression was higher in MG63 cells treated with serum from patients with ankylosing spondylitis or
rheumatoid arthritis than in those treated with serum from controls (both po0.05). The OPG/RANKL ratio was
also higher in MG63 cells treated with serum from ankylosing spondylitis patients than in those treated with
serum from controls (po0.05). No associations were found between the expression of the five genes and the
patient demographics and clinical assessments (all p40.05).
CONCLUSIONS : Serum from ankylosing spondylitis patients increases PPARD, fra-1, MMP7, OPG and RANKL
expression and the OPG/RANKL ratio in MG63 cells; these effects may be due to the stimulatory effect of the
serum on the Wnt pathway.
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’ INTRODUCTION
Ankylosing spondylitis (AS) is a chronic inflammatory
disease characterized by new bone formation that progres-
sively leads to ankylosis and functional disability. The
inflammatory phase of AS shares similarities with other
types of inflammatory arthritis such as rheumatoid arthritis
(RA), with high levels of pro-inflammatory cytokine produc-
tion and osteoclast activity and damage to the cortical bone
of joints (1). However, after the inflammation subsides,
excessive ossification occurs at the site of initial erosion.
Inflammation is often viewed as the inciting cause of
ossification (2,3). Controlling the inflammatory process,
however, does not appear to prevent the development of
ossifications in AS (4). How inflammation is initiated and
how it progresses to bone formation and eventual ankylosis
are poorly understood.
The Wnt signaling pathway plays critical roles in home-
ostasis and bone health in adults. It is involved in
osteoblastogenesis and is regulated in part by inflammation
(5-7). Many studies have suggested a role for the Wnt
pathway in the process of new bone formation in AS, as it
can provide a linkage between inflammation and ossification
(8-12). In the canonical Wnt pathway, the interaction of Wnt
proteins with their receptors leads to increased b-catenin
levels and eventually to the expression of downstream genes
(8). Serum from AS patients can increase b-catenin expres-
sion and these circulating bone formation-inducing b-catenin
molecules are functionally prevalent in AS patients (8).
However, whether the downstream genes of the canonical
Wnt pathway can also be increased by serum from AS
patients has not yet been reported.DOI: 10.6061/clinics/2015(11)04
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Downstream targets of the canonical Wnt pathway include
c-myc, c-jun, cycD, PPARD, fra-1 and MMP7. C-myc
functions as a transcription factor that is associated with a
variety of hematopoietic tumors (13), c-jun is involved in
human malignancies (14) and cycD is another tumor-related
gene (15). PPARD, which influences chondrocyte cell growth
and differentiation (16), may affect height in adults through
effects on osteoclast function (17). Fra-1 plays important roles
in osteoblast differentiation and bone formation that might
be important for the osteogenic differentiation stimulated by
Wnt/b-catenin signaling (18) and MMP7 is involved in the
breakdown of the extracellular matrix in normal physiologi-
cal processes, as well as in disease states such as arthritis and
metastasis (19). Because c-myc, c-jun and cycD are more
related to tumors, whereas PPARD, fra-1 and MMP7 are
considered in many studies to be involved in bone
metabolism, we chose PPARD, fra-1 and MMP7 as the target
genes to be detected.
Osteoprotegerin (OPG) is a protein secreted by osteoblasts
that protects the skeleton from bone resorption via binding
to receptor activator of NF-kB ligand (RANKL) (20). Wnt
pathway activation can increase OPG expression (21).
Whether serum from AS patients can affect OPG and
RANKL expression and have an osteogenic effect through
Wnt pathway regulation has not yet been reported.
In this study, we attempted to explore the effects of serum
from AS patients on the canonical Wnt/b-catenin pathway
by measuring the expression of its downstream target genes
in human osteoblast-like MG63 cells. We also attempted to
detect OPG and RANKL expression to assess whether AS
serum has an osteogenic effect in MG63 cells.
’ MATERIALS AND METHODS
Patients
We recruited 45 patients who fulfilled the modified New
York classification criteria for AS (22), 45 age- and sex-matched
healthy subjects and 30 patients who met the American College
of Rheumatology 1987 revised criteria for RA (23). The healthy
controls were defined by the Nordic questionnaire (24). All
patients were Chinese and were recruited from outpatient
clinics at the Department of Rheumatology of the 3rd Affiliated
Hospital of Sun Yat-sen University. The study was approved
by the local ethics committee and all participants gave
written informed consent, in accordance with the Declaration
of Helsinki.
Disease activity assessment was performed using the Bath AS
Disease Activity Index (BASDAI) and the Bath AS Function
Index (BASFI) in AS patients (25,26). Markers of inflammation
(erythrocyte sedimentation rate [ESR] and C-reactive protein
[CRP] levels) were measured in AS and RA patients. Serum
samples were obtained from all participants and were stored in
aliquots of 250 ml at -20oC. To avoid freeze-thawing, each
experiment was performed with a different aliquot.
Cell culture
Human MG63 osteoblasts obtained from the American Type
Culture Collection (ATCC) were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM, Gibco) supplemented with 10%
fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin
in 6-well plates at a concentration of 2 105/ml and were
incubated in a humidified atmosphere of 5% CO2 at 37
oC for
24 hours. After washing with phosphate-buffered saline
(PBS), 250 ml of serum from either AS or RA patients or from
normal subjects was added into each well and the cells were
cultured with DMEM but without FBS for another 48 hours.
Quantitative real-time PCR
After a total incubation period of 3 days (27), PPARD, fra-1,
MMP7, OPG and RANKL expression in MG63 cells was
measured. Total RNA was isolated using TRIzol reagent
(Invitrogen) and 1 mg of total RNA was converted to cDNA
using the PrimeScriptTM RT reagent kit (TaKaRa). Real-time
PCR reactions were performed using SYBR Premix ExTM Taq
II (TaKaRa) on an ABI PRISM 7000 Sequence Detection
System (Applied Biosystems). The primers used are listed in
Table 1. The following cycling program was used: 15 min
preincubation at 95oC, 10 s denaturation at 95oC and 31 s
annealing at 60oC for 40 cycles. To confirm the amplification
specificity, the PCR products from each primer pair were
subjected to melting curve analysis. Each reaction was
amplified in triplicate and the threshold cycle (Ct) was
calculated using the 2-DDCt method. Relative gene expression
was normalized to GAPDH, used as an internal reference.
Statistical analysis
Statistical analysis was performed using SPSS software.
Variables were tested for normality by applying the
Kolmogorov-Smirnov test. Data are presented as the mean ±
standard deviation (SD) or as percentages, as appropriate.
Correlations between gene expression and other variables were
analyzed using Pearson’s or Spearman’s test, as appropriate.
One-way analysis of variance (ANOVA) and t-tests were used
for group comparisons. P values less than 0.05 (2-tailed) were
considered significant.
’ RESULTS
Characteristics of the study subjects
The demographic and disease characteristics of the study
subjects are shown in Table 2. No significant differences were
found for sex and age between AS patients and healthy
controls (both p40.05). RA patients were older than AS
patients and had shorter symptom durations (both po0.05).
Table 1 - Primers used in real-time PCR.
Gene Forward primer
sequence (5’-3’)
Reverse primer
sequence (5’-3’)
PPARD CTACGGTGTTCATGCATGTGAGG GCACTTCTGGAAGCGGCAGTA
fra-1 GGAGGAAGGAACTGACCGACTTC CTAGGCGCTCCTTCTGCTTCTG
MMP7 GCATGAGTGAGCTACAGTGGGAAC CCACATCTGGGCTTCTGCATTA
OPG TGGCACCAAAGTAAACGCAGAG CTCGAAGGTGAGGTTAGCATGTC
RANKL AAGATGGCACTCACTGCATTTATAG TGATGTGCTGTGATCCAACGA
GAPDH GCACCGTCAAGGCTGAGAAC TGGTGAAGACGCCAGTGGA
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Gene expression detected by quantitative real-
time PCR
The relative PPARD, fra-1, MMP7, OPG and RANKL
mRNA levels are listed in Table 3. The corresponding
p-values for comparisons among the gene expressions in
AS, RA and control serum-treated MG63 cells are listed in
Table 4. When MG63 cells were cultured with AS serum,
PPARD, fra-1, MMP7 and OPG expression was significantly
higher than in cells treated with serum from RA patients or
healthy controls (all po0.05). No significant differences were
found for PPARD, fra-1, MMP7 and OPG expression in MG63
cells treated with serum from RA patients and those treated
with serum from healthy controls (all p40.05). In cells
cultured with AS or RA patient serum, RANKL expression
was higher than that in cells cultured with healthy control
serum (both po0.05); however, the difference in RANKL
expression in cells treated with AS and RA patient serum was
not significant (p40.05). The OPG/RANKL ratio was also
higher in AS serum-treated cells (po0.05), but no significant
difference was found for that of RA-treated cells (p40.05)
compared to control serum-treated cells.
Associations between gene expression and patient
demographics and clinical assessments
The correlation coefficient (r value) and the corresponding
p-value between the gene expression in AS-serum treatedMG63
cells and patient demographics and clinical assessments are
listed in Table 5. In AS patients, no associations were found
between PPARD, fra-1, MMP7, OPG and RANKL expression
and patient demographics and clinical assessments (all p40.05).
’ DISCUSSION
In this study, we measured the effects of serum from AS
patients on human osteoblast-like MG63 cells by detecting
the mRNA expression of downstream target genes of the
canonical Wnt/b-catenin pathway. PPARD, fra-1, MMP7,
OPG and RANKL expression and the OPG/RANKL ratio
were significantly higher in AS serum-treated cells than in
cells treated with serum from RA patients or healthy
controls. We also found that such effects of AS patient serum
were not correlated with age, symptom duration, the
BASDAI, the BASFI, CRP levels or the ESR.
Previous studies have reported that AS serum-treated
Jurkat T cells had higher active b-catenin levels compared
with control serum-treated cells (8). Jurkat T cells are human
peripheral blood leukemia T cells that have been widely
used to explore the Wnt pathway in leukemia (28). MG63
cells, established as an osteoblastic cell line from a human
osteosarcoma, are frequently used to study the mechanism of
bone metabolism. Many studies have adopted MG63 cells as
a model to investigate the Wnt pathway (27,29). The use of
MG63 cells may be advantageous over Jurkat T cells for
researching the role of the Wnt pathway in bone formation,
as MG63 cells have more osteoblast-like characteristics; thus,
the use of MG63 cells in this study makes our results more
convincing.
The Wnt pathway is critically important for normal bone
homeostasis, as the aberrant regulation of bone homeostasis
has been suggested as a key element in the pathogenesis of
AS (8,9). Dickkopf-1 (DKK-1) and sclerostin are the main
inhibitory molecules that regulate the canonical Wnt path-
way. The blockade of DKK-1 was shown to lead to the fusion
of sacroiliac joints in an animal model of arthritis (10).
Altered skeletal expression of sclerostin has also been linked
to radiographic progression in AS (11). A number of studies
have evaluated serum Dkk-1 and sclerostin levels in AS
patients, but conflicting data have been reported (12,30-33).
The net effect of AS serum on the canonical Wnt pathway
(suppression or promotion) remains inconsistent. Rather
than focusing on the circulating concentrations of stimula-
tory or inhibitory molecules of the Wnt pathway in this
study, we evaluated the effect of AS serum by measuring the
expression of downstream genes of the Wnt pathway. We
found that PPARD, fra-1 and MMP7 gene expression was
increased in AS serum-treated MG63 cells. This finding
Table 2 - Demographic and clinical characteristics of the study
subjects.
AS patients RA patients Healthy
controls
Male:female (% male) 39:6 (86.7) 5:25 (16.7) 39:6 (86.7)
Age (years) 28.8 ± 8.9 45.1 ± 12.4 28.9 ± 8.6
Symptom duration
(years)
5.2 ± 4.4 3.8 ± 5.1 NA
HLA-B27 positive (%) 42 (93.3) NA NA
BASDAI 3.7 ± 4.2 NA NA
BASFI 2.8 ± 3.6 NA NA
CRP (mg/l) 21.3 ± 23.7 18.3 ± 22.1 NA
ESR (mm/h) 24.2 ± 20.7 27.2 ± 19.6 NA
Values are the mean ± standard deviation, unless otherwise stated.
AS = ankylosing spondylitis; RA = rheumatoid arthritis; HLA-B27 = human
leukocyte antigen B27; BASDAI = Bath Ankylosing Spondylitis Disease
Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index;
CRP = C-reactive protein (reference range o6 mg/L); ESR = erythrocyte
sedimentation rate (reference range maleo15 mm/h, femaleo20 mm/h);
NA = not applicable.
Table 3 - Relative PPARD, fra-1, MMP7, OPG and RANKL mRNA
levels in MG63 cells cultured with serum from the study subjects.
Serum of subjects
Gene AS patients RA patients Healthy controls
PPARD 1.36 ± 0.98 1.07 ± 0.67 1.00 ± 0.58
fra-1 1.16 ± 0.36 0.88 ± 0.34 1.00 ± 0.38
MMP7 1.89 ± 0.69 1.20 ± 0.95 1.00 ± 0.64
OPG 1.75 ± 1.12 1.15 ± 0.49 1.00 ± 0.54
RANKL 1.49 ± 1.00 1.42 ± 0.91 1.00 ± 0.51
Values are the mean ± standard deviation. AS = ankylosing spondylitis;
RA = rheumatoid arthritis.
Table 4 - P values for comparisons of gene expression among
the ankylosing, rheumatoid arthritis and control serum-treated
MG63 cells.
Comparisons between sera of different subjects
Gene AS vs. control AS vs. RA RA vs. control
PPARD 0.035 0.028 0.234
fra-1 0.043 0.001 0.118
MMP7 0.000 0.028 0.279
OPG 0.000 0.002 0.315
RANKL 0.003 0.917 0.004
AS = ankylosing spondylitis; RA = rheumatoid arthritis.
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supports the notion that the canonical Wnt pathway can be
activated by serum from AS patients.
OPG and RANKL are important molecules in maintaining
the balance of bone metabolism. The OPG/RANKL ratio
increases during the differentiation of pre-osteoblastic cells
into mature osteoblasts (20). Our results demonstrated that
AS patient serum can increase OPG and RANKL expression
and increase the OPG/RANKL ratio, which may eventually
contribute to the formation of new bone. These effects may
also be related to canonical Wnt pathway activation.
According to our data, PPARD, fra-1, MMP7, OPG and
RANKL expression were not correlated with the BASDAI, the
BASFI, CRP levels or the ESR in AS patients. The effects of
inflammation on pathophysiological bone formation in AS
remain contradictory. Despite significant clinical improvement,
cytokine blocking strategies do not overcome new bone
formation in AS, suggesting that the molecular processes
eliciting syndesmophyte formation may differ from those of
inflammation (4). In this study, the lack of correlation between
the expression of downstream genes of the Wnt pathway and
clinical assessments indicated that bone responses may not be
tightly linked to inflammation in AS patients.
In conclusion, serum from AS patients can increase
PPARD, fra-1, MMP7, OPG and RANKL expression and the
OPG/RANKL ratio in MG63 cells. These effects may be due
to the stimulatory effects of AS serum on the Wnt pathway.
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